Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition.

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

Listen as Dr. Jain provides insights into the evolving therapeutic landscape, explaining how the field has expanded beyond single-agent therapy.